# Semaglutide for Alcohol Use Disorder: Read the Placebo Arm

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/semaglutide-for-alcohol-use-disorder

> Heavy drinking days fell 41.1 points on semaglutide and 26.4 points on placebo. The drug's effect is the 13.7-point difference, and it is real, significant and a third of the number that will be quoted.

## Key points

- Heavy drinking days: −41.1 points on semaglutide, −26.4 on placebo.
- The drug's effect is the 13.7-point difference (p=0.0015): real, and a third of the headline.
- n=108, one Danish center, everyone had obesity too, all were treatment-seeking.
- Not approved for this anywhere, and not a reason to buy semaglutide online to cut down.

A 2026 randomized trial gave weekly semaglutide or placebo to 108 people with both alcohol use disorder and obesity. Heavy drinking days fell by **41.1 percentage points** in the semaglutide group. That figure is the one likely to be quoted, and it is the wrong one. The placebo group improved by 26.4 points, so the effect attributable to the drug is **13.7**.[1]

## The result, stated properly

*Change in heavy drinking days from baseline, in percentage points. From the published report.*

| Group | Change | What it means |
| --- | --- | --- |
| Semaglutide | −41.1 (95% CI −48.7 to −33.5) | The number that will be quoted |
| Placebo | −26.4 (95% CI −34.1 to −18.6) | The number that will not be |
| **Treatment difference** | **−13.7 (95% CI −22.0 to −5.4), p=0.0015** | The effect of the drug |

The result is real. The confidence interval comfortably excludes zero, and the trial also reported substantial effects on multiple secondary alcohol-related and physical outcomes.[1] A 13.7 point reduction in heavy drinking days is a meaningful clinical effect in a condition where treatments are few and modest.

> **Why did placebo improve by 26 points?** Because these were treatment-seeking people who enrolled in a trial, were assessed repeatedly, and knew their drinking was being measured. That is what wanting to change, plus structured attention, does, and it is a large part of what any addiction treatment delivers. It is also why a single-arm figure in this field is close to meaningless.

## The same trap in another trial

The placebo arm also did much of the work behind the headline number in the [fatty liver trial](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash): steatohepatitis resolved in 62.9% on semaglutide and in 34.3% on placebo.

> Where being watched helps, as with drinking, the drug’s contribution is a fraction of the raw change.

The pattern is not a quirk of these two studies. Any condition where being watched helps (drinking, eating, adherence, symptom scores) will produce a large placebo response, and the drug’s contribution will be a fraction of the raw change.

## How far this generalizes

- **108 participants**, at a single center in Denmark. Small, and one health system.
- **Everyone had obesity as well as alcohol use disorder.** Whether the effect holds in people with alcohol use disorder and a normal BMI is untested, and it matters, because weight loss itself may be part of the mechanism.
- **All were treatment-seeking.** People who volunteer for an alcohol trial are not a random sample of people who drink heavily.
- **81% completed the intervention**, which is good for this field and still leaves a fifth unaccounted for.

The direction is consistent with a growing body of preclinical and clinical work suggesting GLP-1 receptors are involved in reward and craving, which we cover in [GLP-1s and substance use](https://glpwatchdog.org/research/glp1-and-substance-use). A small randomized trial in people who smoke (24 participants) missed both its primary endpoints,[2] so the effect may not be uniform across substances. For opioids there is no randomized trial yet, only [records data on GLP-1s and opioid use disorder](https://glpwatchdog.org/research/glp1-and-opioid-use-disorder), which links a prescription to fewer overdoses.

## What not to do with this

> **This is not a reason to obtain semaglutide from a telehealth seller to cut down on drinking.** Alcohol use disorder is a condition where withdrawal can be life-threatening and where treatment involves far more than a prescription. No GLP-1 is approved for it anywhere. A trial result is a reason to talk to a clinician who treats addiction, not to go around one.

It is, though, an encouraging result in a field that badly needs them, and one to raise with a doctor if it describes your situation.

## Frequently asked questions

### Does semaglutide reduce drinking?

In a randomized trial of 108 people with both alcohol use disorder and obesity, heavy drinking days fell 41.1 percentage points on semaglutide and 26.4 on placebo, a statistically significant treatment difference of 13.7 points. The drug's contribution is the 13.7, not the 41.

### Why does the placebo number matter so much?

Because it was more than half the total improvement. Treatment-seeking people who enroll in a trial and have their drinking measured repeatedly improve substantially on their own. Quoting the 41-point figure alone overstates the drug's effect roughly threefold.

### Is this approved for alcohol use disorder?

No. No GLP-1 is approved for alcohol use disorder anywhere. This is a single randomized trial of 108 people, and it is a reason for further research and for a conversation with a clinician, not a treatment pathway.

### Would it work for someone who is not overweight?

Untested. Everyone in the trial had obesity as well as alcohol use disorder, and weight loss may itself be part of how the effect works. Whether it holds at a normal BMI is an open question.

### Does it help with other substances too?

Not necessarily. A small randomized trial in people who smoke missed both its primary endpoints. The receptor biology involved in reward and craving is a live research area, but the results so far differ by substance.

## References

1. Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet. 2026. PMID: 42070571. https://pubmed.ncbi.nlm.nih.gov/42070571/
2. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. JAMA Network Open. 2026. PMID: 42189538. https://pubmed.ncbi.nlm.nih.gov/42189538/

---

Cite as: GLP Watchdog, Nora Bissett, "Semaglutide for Alcohol Use Disorder: Read the Placebo Arm", published 2026-08-19, updated 2026-11-01. https://glpwatchdog.org/research/semaglutide-for-alcohol-use-disorder

Canonical HTML page: https://glpwatchdog.org/research/semaglutide-for-alcohol-use-disorder

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
